Detalles de la búsqueda
1.
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Lancet
; 390(10102): 1585-1594, 2017 Sep 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-28755782
2.
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.
BMC Musculoskelet Disord
; 18(1): 174, 2017 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449657
3.
Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension.
J Bone Miner Res
; 32(7): 1481-1485, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28277603
4.
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Lancet Diabetes Endocrinol
; 5(7): 513-523, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28546097
5.
RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.
J Bone Miner Res
; 29(2): 450-7, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23873632
6.
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.
J Clin Endocrinol Metab
; 98(11): 4483-92, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23979955
Resultados
1 -
6
de 6
1
Próxima >
>>